DCVC: Investment Portfolio & Startup News
DCVC
To add a bio or update investment portfolio click update information.
Investment Portfolio


Universal Quantum lands £75m Series A led by DCVC and Firgun Ventures to solve the problem of scale in quantum computing
Universal Quantum builds modular trapped-ion quantum computers designed to reach the scale needed for fault-tolerant, utility-scale quantum computing. Universal Quantum focuses on linking many small quantum chips into manufacturable systems for industry and government partners.


Callosum unlocks a £75m seed round led by Atomico to optimise AI workloads across the best models and chips
Callosum builds a software layer that co-optimises AI models and chips, decomposing each workload and directing every task to the model and processor best suited to execute it. Its platform serves enterprises, next-generation clouds and hyperscalers, and sovereign compute programmes that need frontier AI capability at lower cost and latency, and ships as a family of APIs so developers can adopt new AI hardware without rewriting their applications.


Quantum Motion announces its £120m Series C led by DCVC and Kembara to build silicon quantum computers using standard chip manufacturing
Quantum Motion builds quantum computers using silicon transistors manufactured with the same technology as conventional computer chips. Its systems are designed to reduce cost, space and energy use while fitting into standard data centre infrastructure.


Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform
Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.
- 3(12 months)
- dcvc.com
More venture news
- 16 Nov 2026

ZyaZya lands a £12m Series A round led by Astanor to turn sugar in food into prebiotic fibre
Series AHealth - 13 Nov 2026

Oyster TherapeuticsOyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
Series ALife Sciences - 12 Nov 2026

UFORCEUFORCE secures a £530m Series A round led by Valor Equity Partners and UK National Wealth Fund to build uncrewed defence platforms
Series ADefence